Core Viewpoint - FTSE Russell announced adjustments to several indices including the FTSE China 50 Index, which will take effect after market close on December 19, 2025 [1] Group 1: Index Adjustments - The FTSE China 50 Index will include new constituents such as China Hongqiao (01378), CATL (03750), and Heng Rui Pharmaceutical (01276) [1] - The index will exclude companies like CITIC Securities H (06066), Great Wall Motors H (02333), and Li Auto-W (02015) [1] Group 2: Alternative Stocks - FTSE Russell released a list of alternative stocks for the FTSE China 50 Index, which includes companies like Aluminum Corporation of China (02600), Hansoh Pharmaceutical (03692), Huatai Securities (06886), JD Health (06618), and New China Life Insurance (01336) [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 孫飄揚先生 中國上海 2025年12月3日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-193 江苏恒瑞医药股份有限公司 第九届董事会第二十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的 ...

Core Viewpoint - FTSE Russell announced adjustments to several indices, including the FTSE China 50 Index, which will take effect after the market closes on December 19, 2025, with changes in constituent stocks [1] Group 1: Index Adjustments - The FTSE China 50 Index will include new constituents such as China Hongqiao (01378), CATL (03750), and Heng Rui Pharmaceutical (01276) [1] - The index will remove companies like CITIC Securities H shares (06066), Great Wall Motors H shares (02333), and Li Auto-W (02015) [1] Group 2: Alternative Stocks - FTSE Russell released a list of alternative stocks for the FTSE China 50 Index, which includes companies like Aluminum Corporation of China (02600), Hansoh Pharmaceutical (03692), Huatai Securities (06886), JD Health (06618), and New China Life Insurance (01336) [1]

Core Insights - The article highlights the top and bottom AH share premium rates as of December 3, with Northeast Electric (00042) leading at a premium rate of 900.00% [1][2]. Group 1: Top AH Share Premium Rates - Northeast Electric (00042) has the highest premium rate at 900.00% with H-share priced at 0.270 HKD and A-share at 2.25 CNY [2]. - Hongye Futures (03678) follows with a premium rate of 276.85%, H-share at 3.240 HKD and A-share at 10.19 CNY [2]. - Sinopec Oilfield Service (01033) ranks third with a premium rate of 265.79%, H-share at 0.760 HKD and A-share at 2.32 CNY [2]. Group 2: Bottom AH Share Premium Rates - Contemporary Amperex Technology (03750) has the lowest premium rate at -4.88%, with H-share priced at 473.600 HKD and A-share at 376.08 CNY [2]. - China Merchants Bank (03968) has a premium rate of -0.25%, H-share at 51.650 HKD and A-share at 43.01 CNY [2]. - Heng Rui Medicine (01276) follows with a premium rate of 1.71%, H-share at 71.800 HKD and A-share at 60.97 CNY [2]. Group 3: Premium Deviation Values - Guanghe Communication (00638) has the highest deviation value at 49.00% [1][3]. - Northeast Electric (00042) also features prominently with a deviation value of 36.60% [1][3]. - Chenming Paper (01812) ranks third with a deviation value of 26.74% [1][3]. Group 4: Bottom Premium Deviation Values - GAC Group (02238) has the lowest deviation value at -26.76% [1][3]. - Junsheng Electronics (00699) follows with a deviation value of -18.54% [1][3]. - Jiangsu Ninghu Highway (00177) has a deviation value of -15.01% [1][3].

Core Points - Jiangsu Hengrui Medicine Co., Ltd. has received the acceptance notice from the National Medical Products Administration for its drug application of injectable remimazolam tosylate [2] Group 1 - Drug Name: Injectable Remimazolam Tosylate [2] - Dosage Form: Injectable [2] - Acceptance Number: CXHS2500146 [2] - Application Stage: Market Approval [2] - Applicant: Jiangsu Hengrui Medicine Co., Ltd. [2] - Proposed Indication: Sedation during mechanical ventilation in intensive care [2]

Core Viewpoint - Heng Rui Medicine (01276) has announced the progress of its A-share repurchase plan, indicating a strategic move to enhance shareholder value through share buybacks [1] Group 1: Share Repurchase Details - In November 2025, the company repurchased 979,900 shares through the Shanghai Stock Exchange, accounting for 0.015% of the total share capital, with a maximum purchase price of RMB 63.28 per share and a minimum of RMB 59.32 per share, totaling RMB 59.7885 million (excluding transaction fees) [1] - As of November 30, 2025, the cumulative repurchase amounted to 8,898,700 shares, representing 0.13% of the total share capital, with a maximum price of RMB 70.00 per share and a minimum of RMB 59.32 per share, totaling RMB 595 million (excluding transaction fees) [1]

Core Viewpoint - Heng Rui Medicine (01276) has received the acceptance notice from the National Medical Products Administration for the marketing authorization application of injectable toremifene, indicating progress in its product pipeline [1] Group 1: Product Development - The injectable toremifene has been approved for indications including sedation and anesthesia during non-tracheal intubation surgeries and for induction and maintenance of general anesthesia [1] - The application for market approval is based on two key studies focused on sedation for mechanically ventilated patients in the Intensive Care Unit (ICU) [1] Group 2: Clinical Research - The HR7056-302 study is a Phase III clinical trial evaluating toremifene compared to standard first-line treatments for short-term sedation during critical care, involving 214 patients across 43 centers, led by Professor Guan Xiangdong from Sun Yat-sen University First Affiliated Hospital [1] - The HR7056-206 study is a multi-center Phase II clinical trial assessing toremifene for long-term sedation in critical care, with 24 patients enrolled from 18 centers, led by Professor Shen Feng from Guizhou Medical University Affiliated Hospital [1] - Both studies achieved their primary endpoints as expected [1]

Core Viewpoint - Heng Rui Medicine (01276.HK) has announced a share repurchase plan, indicating a strategic move to enhance shareholder value through buybacks [1] Summary by Categories Share Repurchase Details - As of November 30, 2025, the company has repurchased a total of 8.8987 million shares, which represents 0.13% of the total share capital [1] - The highest purchase price was RMB 70.00 per share, while the lowest was RMB 59.32 per share [1] - The total amount paid for the repurchased shares is RMB 595.2163 million, excluding transaction fees [1]

Core Viewpoint - Jiangsu Hengrui Medicine Co., Ltd. has received the acceptance notice from the National Medical Products Administration for its drug application of injectable remimazolam tosylate, indicating progress in the drug approval process [1] Group 1: Drug Information - Drug Name: Injectable Remimazolam Tosylate [1] - Dosage Form: Injectable [1] - Acceptance Number: CXHS2500146 [1] - Application Stage: Market Approval [1] - Applicant: Jiangsu Hengrui Medicine Co., Ltd. [1] - Proposed Indication: Sedation during mechanical ventilation in intensive care [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-191 江苏恒瑞医药股份有限公司 关于回购公司 ...